Atea Q4 2023 Earnings Report
Key Takeaways
Atea Pharmaceuticals reported its Q4 and full year 2023 financial results, highlighting the rapid enrollment in their Phase 2 HCV combination study and the Phase 3 SUNRISE-3 study. The final results from the lead-in cohort of the Phase 2 combination study confirmed a 98% SVR4 rate. Patient enrollment for SUNRISE-3 has surpassed 1,400 patients, triggering the second interim analysis.
Final results from the lead-in cohort of the Phase 2 HCV combination study confirmed a 98% SVR4 rate.
Enrollment in the Phase 3 SUNRISE-3 study has surpassed 1,400 COVID-19 patients in the monotherapy population.
Two interim analyses by the Independent Data Safety Monitoring Board (DSMB) are planned for the first half of 2024, with topline results expected in the second half of 2024 for the SUNRISE-3 study.
Atea is engaged in efforts directed to the identification of second-generation protease inhibitors as part of a multi-pronged approach against COVID-19.
Atea
Atea
Forward Guidance
Atea anticipates several upcoming events for SUNRISE-3, including the first interim analysis in March 2024, the second interim analysis in the second quarter of 2024, and topline results during the second half of 2024.
Positive Outlook
- First interim analysis expected in March 2024.
- Second interim analysis expected in Q2 2024.
- Topline results from SUNRISE-3 trial anticipated in the second half of 2024.
- Patient enrollment for SUNRISE-3 has correlated with the latest winter wave.
- COVID-19 Program for Second Generation Protease Inhibitors is underway.